Erasca, Inc.
ERAS

$763.36 M
Marketcap
$2.70
Share price
Country
$0.10
Change (1 day)
$3.45
Year High
$1.51
Year Low
Categories

Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.

marketcap

Erasca, Inc. (ERAS) - Company Outlook



Company Outlook

Year Receivables Debt Liabilities Assets Current Assets
2023 -37,216,000 78.61 M 395.3 M 320.68 M
2022 -229,119,000 103.06 M 514.91 M 444.5 M
2021 -341,696,000 44.89 M 501.42 M 420.02 M
2020 -62,390,000 238.81 M 124.83 M 119.99 M
2019 -25,894,000 69.12 M 55.51 M 51.12 M